Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04617327
Other study ID # MUHC-RIMUHC
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 5, 2020
Est. completion date December 31, 2027

Study information

Verified date October 2023
Source McGill University Health Centre/Research Institute of the McGill University Health Centre
Contact Fabio Cury, MD
Phone 514-934-4400
Email fabio.cury@muhc.mcgill.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Soft tissue sarcomas (STSs) are malignant tumours that arise in any of the mesodermal tissues in the body including muscles, fibrous tissues, bone and cartilage, adipose tissue, and blood vessels, most frequently in the extremities (40%), trunk and retroperitoneum (40%). Traditionally, the prescription schedule for conventional preoperative RT is a regimen of 50 Gy in fractions of 1.8-2 Gy per day. Concerns regarding this regimen include the delay to definitive surgery and the higher rate of wound complications compared to post-operative radiotherapy. Hypofractionated RT is a prescription schedule in which the total dose of radiation is delivered in larger doses per fraction in fewer fractions allowing the delivery of a higher biologically effective dose (BED) to the tumour than with conventional RT [7] during a shorter period of time.


Description:

This will be a phase I/II study of hypofractionation delivering five fractions (one fraction delivered every 2nd day) of 7 Gy of external beam radiotherapy over 5 fractions (one and half week period) in patients with localized STSs who are planned to receive pre-operative radiotherapy. Patients will undergo surgery 4-6 weeks after completion of RT. Pre-treatment evaluation will be according to standard practice: History and Physical Exam - height, - weight - history (diabetes, vascular disease) Radiology - MRI of primary site or - CT if MRI not tolerated - CT chest Quality of Life - Musculoskeletal Tumour Society Rating Scale - Toronto Extremity Salvage Score (TESS) Follow-up assessment will be done as follows: History and Physical Exam - Acute radiation toxicity - During RT and 2 weeks after end of RT Acute surgical toxicity - wound assessment - At hospital discharge, - 2 weeks post-surgery - 1 month post-surgery - 3 months post-surgery - 6 months post-surgery Late toxicity (skin, subcutaneous, bone, joint) & peripheral limb edema - Every 6 months thereafter Radiology - Chest CT-scan - Within 1 month pre-surgery - Standard thereafter MRI or CT scan of primary site - Prior to surgery, as standard - Every 3-6 months or as needed after surgery Quality of life Questionnaires - Toronto Extremity Salvage Score (TESS - Musclo Tumor Rating Scale (MSTS) - At months 1,3,6, 12, 18 and 24 after surgery. - Yearly thereafter up to 5 years


Recruitment information / eligibility

Status Recruiting
Enrollment 15
Est. completion date December 31, 2027
Est. primary completion date January 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically proven STS of the extremities, above the knee, or trunk following review by our pathologist - Lesions smaller than 15cm in largest dimension - Deemed appropriate for preoperative radiotherapy and conservative surgery following patient assessment by a radiation oncologist and surgical oncologist - Lesion is primary or locally recurrent. Patients who underwent unplanned non-oncological excision ("whoops" procedure) at a referring hospital are NOT eligible - No previous radiation therapy - ECOG 0-2 (or Karnofsky Performance Status = 70) within 60 days prior to registration - Resectable primary lesion with or without distant metastasis - Age = 18 - Patient must be able to provide study-specific informed consent prior to study entry - Patient is available for treatment and follow-up Exclusion Criteria: - Patients who underwent unplanned non-oncological excision ("whoops" procedure) at a referring hospital - Lesions below the knee - Prior or concurrent invasive malignancy (except non-melanomatous skin cancer) or lymphomatous/hematogenous malignancy, unless continually disease free for a minimum of 5 years - Regional lymph node involvement - Previous irradiation to the area to be treated - Other major medical illness deemed to preclude safe administration of protocol treatment or required follow-up

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Hypofractionation
Shorter radiation therapy means that a higher dose will be given on a daily basis. The goal is to target microscopic disease and decrease the chances of local recurrence. Organs at risk (OAR) will receive doses following the constraints from the Timmerman tables used for reference when using 5 or more fractions of EBRT. Treatment will be delivered every 2nd day, for a maximum of 3 fractions per week. Daily pretreatment Image Guided Radiotherapy Images (IGRT) (Cone-Beam CT - CBCT) will be co-registered with the CT simulation dataset to adjust patient position before each treatment by matching the bone adjacent to the planned tumour volume (PTV). Treatment will be administered if there is <3 mm in any dimension, or rotation is <3 degrees. If the isocentre set-up exceeds 3 mm at any given treatment session, the treatment couch will be translated to restore its planned position.

Locations

Country Name City State
Canada McGill University Health Centre-Cedars Cancer Centre Montréal Quebec

Sponsors (1)

Lead Sponsor Collaborator
McGill University Health Centre/Research Institute of the McGill University Health Centre

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acute RadiationToxicity using Common Terminology Criteria for Adverse Events (CTCAE) V.5 To assess, skin reactions and wound healing 1 month
Secondary Physicians Muscle Tumor Rating Scale To assess the amount of difficulty performing activities, including motion, strength and stability 1 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04577014 - Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma Phase 1/Phase 2
Recruiting NCT04656262 - Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients Phase 3
Recruiting NCT03077178 - Impact of Locoregional Treatment of Soft Tissue Sarcoma on Status of Patients Aged 70 Years and Over N/A
Not yet recruiting NCT06110650 - A Study of Surufatinib in the Treatment of Advanced Soft Tissue Sarcoma N/A
Terminated NCT03735758 - Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib Phase 4
Not yet recruiting NCT03951571 - Efficacy and Safety of Anlotinib in Adjuvant Therapy for High-grade Soft Tissue Sarcoma Phase 2
Enrolling by invitation NCT03134742 - Radiation Effects on Bone
Not yet recruiting NCT06252727 - Fluorescent Aided Resection and Evaluation of Soft Tissue Sarcomas (FLARES) Phase 1
Recruiting NCT06385288 - Blood and Tissue Extraction for Immunological Examinations During Neoadjuvant Therapy of Soft Tissue Sarcomas N/A
Recruiting NCT05116254 - Sarcomas and DDR-Inhibition; a Combined Modality Study Phase 1
Active, not recruiting NCT03526679 - Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma Phase 1/Phase 2
Recruiting NCT04008238 - Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients N/A
Recruiting NCT04095208 - Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study Phase 2
Recruiting NCT04330456 - Combined Treatment of Patients With Soft Tissue Sarcoma Including Preoperative Stereotactic Radiation Therapy and Postoperative Conformal Radiation Therapy N/A
Completed NCT03833037 - Study of a Cohort of Cases of Synovial Sarcoma Treated in the Orthopedic Surgery and Traumatology Department of the Hospital de Sant Pau Between 1983 and 2016
Completed NCT03056599 - Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma Phase 1
Recruiting NCT05961761 - Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients Phase 2
Recruiting NCT06273852 - A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors Early Phase 1
Recruiting NCT05182164 - Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas Phase 2
Withdrawn NCT03104335 - Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial Phase 2